Geode Capital Management LLC lifted its position in Masimo Co. (NASDAQ:MASI - Free Report) by 1.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 792,886 shares of the medical equipment provider's stock after acquiring an additional 11,984 shares during the period. Geode Capital Management LLC owned 1.48% of Masimo worth $105,741,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also added to or reduced their stakes in MASI. Barclays PLC increased its holdings in Masimo by 152.6% in the 3rd quarter. Barclays PLC now owns 39,957 shares of the medical equipment provider's stock worth $5,329,000 after acquiring an additional 24,137 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Masimo in the third quarter worth approximately $519,000. MML Investors Services LLC lifted its holdings in Masimo by 4.9% during the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider's stock valued at $274,000 after buying an additional 96 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Masimo during the 3rd quarter worth $2,288,000. Finally, National Bank of Canada FI raised its stake in Masimo by 195.6% in the third quarter. National Bank of Canada FI now owns 132,500 shares of the medical equipment provider's stock worth $17,666,000 after buying an additional 87,675 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.
NASDAQ MASI opened at $170.63 on Thursday. The company has a 50-day moving average price of $159.31 and a two-hundred day moving average price of $134.19. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The stock has a market cap of $9.14 billion, a price-to-earnings ratio of 117.68 and a beta of 1.01. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $180.97.
Masimo (NASDAQ:MASI - Get Free Report) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. During the same quarter last year, the business posted $0.63 EPS. The company's revenue for the quarter was up 5.4% on a year-over-year basis. Analysts forecast that Masimo Co. will post 4.03 EPS for the current year.
A number of brokerages have issued reports on MASI. Wells Fargo & Company upped their price target on shares of Masimo from $171.00 to $193.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. BTIG Research raised their target price on Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Piper Sandler boosted their price target on shares of Masimo from $180.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday. Raymond James upgraded Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 target price for the company in a report on Wednesday, November 6th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a research report on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $175.67.
Get Our Latest Research Report on Masimo
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.